Andreas Halvorsen's hedge fund firm Viking Global recently filed a 13G with the SEC on shares of Medivation (MDVN). Per the filing, Viking has revealed a 5.3% ownership stake in MDVN with just over 1.9 million shares.
This is a brand new position for the hedge fund and the SEC filing was required due to portfolio activity on August 8th.
Per Google Finance, Medivation is "a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the Company is developing MDV3100 for multiple stages of advanced prostate cancer."
You can view the rest of Viking Global's US stock portfolio in the brand new issue of our Hedge Fund Wisdom newsletter.
Tuesday, August 28, 2012
Viking Global Starts Medivation Stake (MDVN)
blog comments powered by Disqus
